In 2024-2028, ODIN will focus on areas that holds a strong potential for the Danish ecosystem and global health in general.   

The main focus will be on drug discovery and better diagnostics within three disease areas that pose major threats to human health:

Projects within these three areas are expected to explore e.g. new disease models, biomarkers, targets, tools and other precompetitive niches that can lead to improved drug discovery and clinical diagnostics.

Up to 1/3 of the funding reserved for research projects will have a more “open-ended” focus. 

Calls within this frame will focus on cross-disciplinary projects exploring disease-agnostic technology platforms and research tools/methods that potentially can lead to improved drug discovery and clinical diagnostics. 

The aim is to facilitate projects and approaches that are expected to generate valuable knowledge applicable to more diseases and unmet needs. Such projects can explore, for example, a technology platform or research tools and methods within a single disease area and/or use one disease as model - as long as the project will expectedly provide results that can be transferred to other disease areas. 

As such, projects can be explored through any disease area or approach, including but not limited to, regenerative medicine/stem cells, microbiome in relation to human health and rare diseases. The ODIN Steering Group has the mandate to issue specialized calls within strategic areas of interest in the future – including biosolutions.  

All projects, regardless of call focus, must be precompetitive, open and designed to meet ODIN’s selection criteria and aim (see folder on Call Guidelines under "About ODIN").